6735-33-7

Usage

Uses

Used in Pharmaceutical Research:
MDPPT is utilized as a research chemical for the study of its psychoactive effects and potential applications in the treatment of certain neurological or psychiatric conditions. Its role as a norepinephrine-dopamine reuptake inhibitor makes it a subject of interest for understanding the mechanisms of stimulant action and addiction.
Used in Forensic Toxicology:
MDPPT is employed in forensic toxicology as a marker for the detection and identification of controlled substances in cases involving drug abuse or intoxication. Its presence can be indicative of illegal substance use or distribution.
Used in Regulatory Compliance:
MDPPT is used by law enforcement agencies to ensure compliance with controlled substance regulations. Its detection in controlled environments or individuals can lead to legal actions and enforcement of drug control policies.

Upstream product

• 26272-83-3 oxetan-3-yl 4-methylbenzenesulfonate 
• 108-95-2 phenol 

Relevant academic research and scientific papers

Mild C–C Bond Formation via Lewis Acid Catalyzed Oxetane Ring Opening with Soft Carbon Nucleophiles

Mild oxetane opening by soft carbon nucleophiles has been developed for efficient C?C bond formation. In the presence of LiNTf2 or TBSNTf2 as catalyst, silyl ketene acetals were found to be effective nucleophiles to generate a wide range of highly oxygenated molecules, which are key substructure in natural products like polyketides. Furthermore, intramolecular oxetane opening by a styrene-based carbon nucleophile via a Prins-type process was also achieved with Sc(OTf)3 as catalyst, leading to efficient formation of the useful 2,3-dihydrobenzo[b]oxepine skeleton.

Highly Enantioselective, Hydrogen-Bond-Donor Catalyzed Additions to Oxetanes

A precisely designed chiral squaramide derivative is shown to promote the highly enantioselective addition of trimethylsilyl bromide (TMSBr) to a broad variety of 3-substituted and 3,3-disubstituted oxetanes. The reaction provides direct and general access to synthetically valuable 1,3-bromohydrin building blocks from easily accessed achiral precursors. The products are readily elaborated both by nucleophilic substitution and through transition-metal-catalyzed cross-coupling reactions. The enantioselective catalytic oxetane ring opening was employed as part of a three-step, gram-scale synthesis of pretomanid, a recently approved medication for the treatment of multidrug-resistant tuberculosis. Heavy-atom kinetic isotope effect (KIE) studies are consistent with enantiodetermining delivery of bromide from the H-bond-donor (HBD) catalyst to the activated oxetane. While the nucleophilicity of the bromide ion is expected to be attenuated by association to the HBD, overall rate acceleration is achieved by enhancement of Lewis acidity of the TMSBr reagent through anion abstraction.